Key statistics
On Thursday, Halozyme Therapeutics Inc (HALO:NSQ) closed at 45.70, 37.86% above the 52 week low of 33.15 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 45.85 |
---|---|
High | 46.12 |
Low | 44.80 |
Bid | 45.70 |
Offer | 46.20 |
Previous close | 45.76 |
Average volume | 2.95m |
---|---|
Shares outstanding | 127.23m |
Free float | 125.85m |
P/E (TTM) | 15.14 |
Market cap | 5.82bn USD |
EPS (TTM) | 3.02 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
- Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
- HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
- Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
- Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
- Halozyme to Present at Upcoming Investor Conferences
More ▼